Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million in Series B financing. Listed firm Syncona committed £19.9m as part of a syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion and British Patient Capital. Syncona founded Purespring in 2020 as one of the … Continue reading Purespring raises £80m to target kidney disease